Gary Raskob to Aged
This is a "connection" page, showing publications Gary Raskob has written about Aged.
Connection Strength
2.161
-
Association Between Asymptomatic Proximal Deep Vein Thrombosis and Mortality in Acutely Ill Medical Patients. J Am Heart Assoc. 2021 02; 10(5):e019459.
Score: 0.093
-
Incidence of Venous Thromboembolism in a Racially Diverse Population of Oklahoma County, Oklahoma. Thromb Haemost. 2021 Jun; 121(6):816-825.
Score: 0.092
-
Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients. J Am Coll Cardiol. 2020 06 30; 75(25):3140-3147.
Score: 0.089
-
Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial. JAMA. 2020 01 14; 323(2):130-139.
Score: 0.086
-
Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study. J Thromb Haemost. 2019 11; 17(11):1866-1874.
Score: 0.083
-
Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the MAGELLAN Study. Clin Appl Thromb Hemost. 2019 Jan-Dec; 25:1076029619886022.
Score: 0.080
-
Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study. Thromb Haemost. 2018 Aug; 118(8):1439-1449.
Score: 0.078
-
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med. 2018 Feb 15; 378(7):615-624.
Score: 0.074
-
Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematol. 2016 Aug; 3(8):e379-87.
Score: 0.067
-
Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematol. 2016 May; 3(5):e228-36.
Score: 0.066
-
The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications. Thromb Haemost. 2016 06 02; 115(6):1240-8.
Score: 0.066
-
Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. A sub-analysis of the AMPLIFY trial. Thromb Haemost. 2016 Apr; 115(4):809-16.
Score: 0.065
-
The economic burden of incident venous thromboembolism in the United States: A review of estimated attributable healthcare costs. Thromb Res. 2016 Jan; 137:3-10.
Score: 0.065
-
Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: the Borealis-Atrial Fibrillation Study. J Thromb Haemost. 2014 Jun; 12(6):824-30.
Score: 0.058
-
Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials. J Bone Joint Surg Br. 2012 Feb; 94(2):257-64.
Score: 0.050
-
Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study. Thromb Haemost. 2010 Sep; 104(3):642-9.
Score: 0.044
-
Exclusion of first-episode deep-vein thrombosis after-hours using D-dimer. Blood Coagul Fibrinolysis. 2007 Dec; 18(8):795-800.
Score: 0.037
-
Extended prophylaxis of venous thromboembolism with idraparinux. N Engl J Med. 2007 Sep 13; 357(11):1105-12.
Score: 0.037
-
Clinical utility of D-dimer in patients with suspected pulmonary embolism and nondiagnostic lung scans or negative CT findings. Chest. 2004 Mar; 125(3):851-5.
Score: 0.029
-
A cost-effectiveness analysis of fondaparinux sodium compared with enoxaparin sodium as prophylaxis against venous thromboembolism: use in patients undergoing major orthopaedic surgery. Pharmacoeconomics. 2004; 22(9):605-20.
Score: 0.028
-
ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood. 2003 Jul 01; 102(1):60-8.
Score: 0.027
-
Milvexian for the Prevention of Venous Thromboembolism. N Engl J Med. 2021 12 02; 385(23):2161-2172.
Score: 0.024
-
Long-Term Risk for Major Bleeding During Extended Oral Anticoagulant Therapy for First Unprovoked Venous Thromboembolism : A Systematic Review and Meta-analysis. Ann Intern Med. 2021 10; 174(10):1420-1429.
Score: 0.024
-
Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or older. J Thromb Haemost. 2021 11; 19(11):2772-2780.
Score: 0.024
-
Abelacimab for Prevention of Venous Thromboembolism. N Engl J Med. 2021 08 12; 385(7):609-617.
Score: 0.024
-
Withholding treatment in patients with acute pulmonary embolism who have a high risk of bleeding and negative serial noninvasive leg tests. Am J Med. 2000 Sep; 109(4):301-6.
Score: 0.022
-
Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER Trials. Thromb Haemost. 2020 Mar; 120(3):515-524.
Score: 0.022
-
Extended vs. standard-duration thromboprophylaxis in acutely ill medical patients: A systematic review and meta-analysis. Thromb Res. 2019 Dec; 184:58-61.
Score: 0.021
-
Randomized phase 2 trial comparing JNJ-9375, a thrombin-directed antibody, with apixaban for prevention of venous thrombosis. J Thromb Haemost. 2019 12; 17(12):2081-2088.
Score: 0.021
-
Characteristics and Outcomes in Patients with Venous Thromboembolism Taking Concomitant Anti-Platelet Agents and Anticoagulants in the AMPLIFY Trial. Thromb Haemost. 2019 Mar; 119(3):461-466.
Score: 0.020
-
Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness. N Engl J Med. 2018 Sep 20; 379(12):1118-1127.
Score: 0.020
-
The prothrombin time does not predict the risk of recurrent venous thromboembolism or major bleeding in rivaroxaban-treated patients. Thromb Res. 2018 10; 170:75-83.
Score: 0.020
-
Risk Scores for Occult Cancer in Patients with Venous Thromboembolism: A Post Hoc Analysis of the Hokusai-VTE Study. Thromb Haemost. 2018 Jul; 118(7):1270-1278.
Score: 0.019
-
Clinical Impact and Course of Anticoagulant-Related Major Bleeding in Cancer Patients. Thromb Haemost. 2018 01; 118(1):174-181.
Score: 0.019
-
Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: An analysis of the randomized, double-blind Hokusai-VTE trial. Thromb Res. 2018 02; 162:7-14.
Score: 0.019
-
Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE Study. Thromb Haemost. 2017 12; 117(12):2406-2414.
Score: 0.019
-
Clinical impact of major bleeding in patients with venous thromboembolism treated with factor Xa inhibitors or vitamin K antagonists. Thromb Haemost. 2017 Oct; 117(10):1944-1951.
Score: 0.019
-
Clinical decisions in idiopathic thrombocytopenic purpura. Hosp Pract (1995). 1997 Sep 15; 32(9):159-60, 163-6, 169-70, passim.
Score: 0.018
-
Clinical impact of major bleeding in patients with venous thromboembolism treated with factor Xa inhibitors or vitamin K antagonists. An individual patient data meta-analysis. Thromb Haemost. 2017 10 05; 117(10):1944-1951.
Score: 0.018
-
Prediction of major and clinically relevant bleeding in patients with VTE treated with edoxaban or vitamin K antagonists. Thromb Haemost. 2017 04 03; 117(4):784-793.
Score: 0.018
-
Monitoring low-dose warfarin therapy by a central laboratory and implications for clinical trials and patient care. The Coumadin Aspirin Reinfarction (CARS) Pilot Study Group. Am J Cardiol. 1996 Nov 01; 78(9):1074-6.
Score: 0.017
-
Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematol. 2016 Sep; 3(9):e437-45.
Score: 0.017
-
Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. Thromb Haemost. 2016 Sep 27; 116(4):747-53.
Score: 0.017
-
Aging and heparin-related bleeding. Arch Intern Med. 1996 Apr 22; 156(8):857-60.
Score: 0.017
-
Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. J Thromb Haemost. 2015 Dec; 13(12):2187-91.
Score: 0.016
-
Global public awareness of venous thromboembolism. J Thromb Haemost. 2015 Aug; 13(8):1365-71.
Score: 0.016
-
Cost effectiveness of diagnosis of deep vein thrombosis in symptomatic patients. Thromb Haemost. 1995 Jul; 74(1):189-96.
Score: 0.016
-
Effect of treatment with low-dose warfarin-aspirin on activated factor VII. Blood. 1995 Jun 01; 85(11):3034-9.
Score: 0.016
-
Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med. 2015 Jan 15; 372(3):232-40.
Score: 0.015
-
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013 Oct 10; 369(15):1406-15.
Score: 0.014
-
Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013 Aug 29; 369(9):799-808.
Score: 0.014
-
Apixaban after hip or knee arthroplasty versus enoxaparin: efficacy and safety in key clinical subgroups. J Thromb Haemost. 2013 Mar; 11(3):444-51.
Score: 0.013
-
Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013 02 21; 368(8):699-708.
Score: 0.013
-
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012 04 05; 366(14):1287-97.
Score: 0.013
-
Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial. Lancet. 2012 Jan 14; 379(9811):123-9.
Score: 0.012
-
Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials. BMJ. 2011 May 24; 342:d3036.
Score: 0.012
-
Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010 Dec 23; 363(26):2487-98.
Score: 0.011
-
Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010 Dec 23; 363(26):2499-510.
Score: 0.011
-
A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery. Thromb Haemost. 2010 Dec; 104(6):1150-7.
Score: 0.011
-
Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the Van Gogh DVT trial. Thromb Haemost. 2010 Jul; 104(1):86-91.
Score: 0.011
-
Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010 Mar 06; 375(9717):807-15.
Score: 0.011
-
Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009 Aug 06; 361(6):594-604.
Score: 0.010
-
Scoring and psychometric validation of the Perception of Anticoagulant Treatment Questionnaire (PACT-Q). Health Qual Life Outcomes. 2009 Apr 07; 7:30.
Score: 0.010
-
Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thromb Haemost. 2009 Apr; 101(4):762-9.
Score: 0.010
-
A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. Blood. 2008 Sep 15; 112(6):2242-7.
Score: 0.010
-
Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009 Jan; 24(1):1-9.
Score: 0.010
-
Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials. J Thromb Haemost. 2007 Jun; 5(6):1191-4.
Score: 0.009
-
Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med. 2006 Dec; 119(12):1062-72.
Score: 0.009
-
Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med. 2004 Jun 01; 140(11):867-73.
Score: 0.007
-
Initial management of immune thrombocytopenic purpura in adults: a randomized controlled trial comparing intermittent anti-D with routine care. Am J Hematol. 2003 Nov; 74(3):161-9.
Score: 0.007
-
Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med. 2003 Oct 30; 349(18):1695-702.
Score: 0.007
-
Pulmonary angiography, ventilation lung scanning, and venography for clinically suspected pulmonary embolism with abnormal perfusion lung scan. Ann Intern Med. 1983 Jun; 98(6):891-9.
Score: 0.007
-
Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement. Circulation. 2001 Jul 03; 104(1):74-8.
Score: 0.006
-
Predictive value of compression ultrasonography for deep vein thrombosis in symptomatic outpatients: clinical implications of the site of vein noncompressibility. Arch Intern Med. 2000 Feb 14; 160(3):309-13.
Score: 0.005
-
Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism. American-Canadian Thrombosis Study Group. Arch Intern Med. 2000 Jan 24; 160(2):229-36.
Score: 0.005
-
Underuse of venous thromboembolism prophylaxis for general surgery patients: physician practices in the community hospital setting. Arch Intern Med. 1998 Sep 28; 158(17):1909-12.
Score: 0.005
-
The clinical validity of normal compression ultrasonography in outpatients suspected of having deep venous thrombosis. Ann Intern Med. 1998 Jan 01; 128(1):1-7.
Score: 0.005
-
Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. An economic perspective. Arch Intern Med. 1997 Feb 10; 157(3):298-303.
Score: 0.004
-
The low-probability lung scan. A need for change in nomenclature. Arch Intern Med. 1995 Sep 25; 155(17):1845-51.
Score: 0.004
-
Safety and anticoagulation effect of a low-dose combination of warfarin and aspirin in clinically stable coronary artery disease. Coumadin Aspirin Reinfarction (CARS) Pilot Study Group. Am J Cardiol. 1994 Oct 01; 74(7):657-61.
Score: 0.004
-
Physician-guided treatment compared with a heparin protocol for deep vein thrombosis. Arch Intern Med. 1994 May 09; 154(9):999-1004.
Score: 0.004
-
A noninvasive strategy for the treatment of patients with suspected pulmonary embolism. Arch Intern Med. 1994 Feb 14; 154(3):289-97.
Score: 0.004
-
A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med. 1993 Nov 04; 329(19):1370-6.
Score: 0.004
-
Duplex ultrasonography for the detection of deep vein thrombi after total hip or knee arthroplasty. Angiology. 1993 Jan; 44(1):26-33.
Score: 0.003
-
Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med. 1990 May 03; 322(18):1260-4.
Score: 0.003
-
Predicting the daily prothrombin time response to warfarin. Ther Drug Monit. 1990 May; 12(3):246-9.
Score: 0.003
-
Clinical validity of a normal perfusion lung scan in patients with suspected pulmonary embolism. Chest. 1990 Jan; 97(1):23-6.
Score: 0.003
-
Pharmacokinetics and dynamics of heparin in patients with proximal vein thrombosis. J Clin Pharmacol. 1989 Oct; 29(10):896-900.
Score: 0.003
-
Pulmonary embolism in outpatients with pleuritic chest pain. Arch Intern Med. 1988 Apr; 148(4):838-44.
Score: 0.002
-
Diagnostic value of ventilation-perfusion lung scanning in patients with suspected pulmonary embolism. Chest. 1985 Dec; 88(6):819-28.
Score: 0.002